Histological evaluation of colorectal liver metatases with or without chemotherapy

Histological evaluation of colorectal liver metatases with or without chemotherapy - Histological effect of chemotherapy on colorectal liver metastases

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050894

Enrollment

Registered

2023-04-20

Start date

2020-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal liver metastases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who enrolled a multicenter randomized phase III trial to compare surgery followed by postoperative FOLFOX regimen with perioperative FOLFOX regimen plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases

Exclusion criteria

Exclusion criteria: The patients who declined. The patients who were judged unsuitable for the study

Design outcomes

Primary

Measure	Time frame
Frequency of micrometatases around colorectal liver metastases	—

Secondary

Measure	Time frame
Distance from colorectal liver metastases to micrometatases Thickness of pseudocapsule around colorectal liver metastases	—

Countries

Japan

Contacts

Public ContactMasaru Matsumura

Tokyo university Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery

team-ma22n@hotmail.co.jp03-3815-5411

Outcome results